NATiV3 Phase 3 readout is the single event that determines whether Inventiva's pan-PPAR bet in MASH justifies its reconstructed balance sheet

Updated 13d ago

Inventiva is a clinical-stage biotech company developing lanifibranor, a targeted liver drug for metabolic dysfunction-associated fatty liver disease (MASH), which is not yet approved.

Inventiva rebuilt its capital structure around one asset: lanifibranor, a pan-PPAR agonist for MASH, a fibrotic liver disease with limited approved options. A €178M financing overhaul in 2026 extended runway to Q1 2028, but Tranche C (€55M) and Tranche 3 warrants (€116M) are contingent on NATiV3 hitting its primary endpoint. Approvability rests entirely on unblinded Phase 3 data from a single trial, with GLP-1 agonists from better-capitalized rivals reshaping the MASH competitive landscape before lanifibranor reaches market.

Status

Challenged

Conviction

Current Thesis Drivers

BTD granted for lanifibranor in MASH (2020)
€178M 2026 financing closed; EIB debt fully repaid
NATiV3 1,009-patient Phase 3 last visit completed; readout imminent
Tranche C (€55M) and Tranche 3 warrants (€116M) contingent on NATiV3 success

What could change the thesis?

NATiV3 readout Q4 2026: positive unlocks financing and submission; miss forecloses both
Tranche C issuance: endpoint hit triggers €55M; miss leaves funding gap before approval
GLP-1/GCG rivals (pemvidutide): approval before lanifibranor shrinks addressable market

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

1 programs · 5 catalysts

Stress Test